Our Technology
OncoTEX is developing TEX Core
TEX Core, a world-first oncology drug platform designed to create innovative therapies capable of overcoming multiple limitations often associated with current cancer therapeutics, including the predominant platinum-based resistance.
OxaliTEX is the first clinical candidate developed from the TEX Core platform, designed to target platinum-resistant ovarian cancer
tumour cells by overcoming issues associated with the current platinum-based standard of care (SOC) and is being developed for
platinum-resistant ovarian cancer. Unlike current platinum-based SOC oncology therapeutics, OxaliTEX is tumour localising, well-
tolerated, overcomes platinum-resistance, and is MRI-detectable, allowing clinicians and patients to easily monitor tumour regression
during treatment.
OncoTEX has further enriched its pipeline with three additional drug candidates.
- GemTEX (exploring the use of DNA replication inhibitors)
- ParpTEX (exploring the use of PARP inhibitors) are part of our Chemotherapy program
- MangaTEX is part of our Photothermal program
OXALITEX: THE FIRST TEX CORE COMPOUND
The first TEX Core oncology compound to be developed is OxaliTEX, which localizes to solid tumors including ovarian, lung and colorectal cancers.
OxaliTEX activates within cancer cells, overcoming multiple mechanisms of resistance and minimizing toxic side effects. The lead indication for OxaliTEX is ovarian cancer, the number one cause of gynecological cancer deaths globally.